HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Opioid Label For Kratom Called Misbranding By Marketers

This article was originally published in The Rose Sheet

Executive Summary

"Based on the scientific information in the literature and further supported by our computational modeling and the reports of its adverse effects in humans, we feel confident in calling compounds found in kratom, opioids," says Commissioner Scott Gottlieb.


Related Content

Kratom Industry Group Has First Qualifier For Its GMP Standards Exceeding FDA's
Ohio's Proposed Ban On Sales Marks Kratom Industry's Latest Battlefront
Warnings On Kratom Opioid Withdrawal Claims Mark Tip Of FDA Concerns
Kratom Group Sharpens Criticism Of 'Opioid' Finding In FDA's Report To DEA
Kratom Experts Seek NIDA As Ally To Show Herb's Safety And Benefits
FDA Turns Kratom's Future In US Dietary Supplement Market Into History
DEA Proposal To Schedule Kratom Stirs Wave Of Opposition
FDA Kicks Off Kratom Enforcement With $400,000 Seizure In Illinois
Kratom Import Alert Clarifies FDA Deems The Botanical An Unsafe NDI
Kratom Action Presents Regulatory Puzzle For FDA





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts